New combo therapy aims to outsmart tough leukemia

NCT ID NCT04560322

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of three drugs (venetoclax, obinutuzumab, and acalabrutinib) in 40 people with relapsed or refractory CLL or SLL. The treatment is adjusted based on how well the cancer responds (measured by minimal residual disease). The main goal is to see if at least 90% of participants are alive after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax, obinutuzumab, and acalabrutinib
What this could lead to: If successful, this could offer a more personalized treatment approach for people with hard-to-treat CLL or SLL, potentially improving survival and reducing the need for further therapy.
What could go wrong: This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. The drugs can cause serious side effects like infections or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.